Alzheimer Disease

Neurology
88
Pipeline Programs
30
Companies
50
Clinical Trials
8 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
32
6
30
1
14
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
360%
Small Molecule
240%
+ 101 programs with unclassified modality

On Market (4)

Approved therapies currently available

Novartis
EXELONApproved
rivastigmine
Novartis
Cholinesterase Inhibitor [EPC]transdermal2007
U
GALANTAMINE HYDROBROMIDEApproved
galantamine
Unknown Company
oral2016
J&
RAZADYNEApproved
galantamine hydrobromide
Johnson & Johnson
oral2001
J&
RAZADYNE ERApproved
galantamine hydrobromide
Johnson & Johnson
oral2005

Competitive Landscape

55 companies ranked by most advanced pipeline stage

J&
4 programs
4
1
galantaminePhase 31 trial
galantamine hydrobromidePhase 31 trial
galantamine hydrobromidePhase 31 trial
galantamine hydrobromidePhase 31 trial
Active Trials
NCT00304629Completed241Est. Mar 2002
NCT00253188Completed653Est. Dec 1998
NCT00261573Completed593Est. Dec 2000
+1 more trials
Novartis
NovartisBASEL, Switzerland
1 program
1
1
RivastigminePhase 31 trial
Active Trials
NCT00000174Completed
OD
1 program
1
galantaminePhase 4
Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
7 programs
2
1
3
FlorbetabenPhase 31 trial
Nilotinib BE 84mgPhase 31 trial
[18F]PI-2620Phase 31 trial
FlorbetabenPhase 21 trial
FlorbetabenPhase 11 trial
+2 more programs
Active Trials
NCT05326009Unknown60Est. May 2023
NCT01138111CompletedEst. Dec 2011
NCT04715750CompletedEst. Oct 2022
+4 more trials
Eli Lilly and Company
4 programs
1
2
DonanemabPhase 3Monoclonal Antibody1 trial
P-tau217 TestPhase 31 trial
LY3002813Phase 11 trial
Flutemetamol F18 InjectionN/A
Active Trials
NCT02624778Completed61Est. Aug 2019
NCT05508789Recruiting1,500Est. Jul 2028
NCT07142954Recruiting3,400Est. Jul 2033
Sanofi
SanofiPARIS, France
4 programs
1
2
1
xaliprodenPhase 32 trials
SR57667BPhase 21 trial
SR57667BPhase 21 trial
AVE1625Phase 1/21 trial
Active Trials
NCT00380302Completed162Est. Jul 2007
NCT00285025Completed500Est. Sep 2005
NCT00285077Completed390Est. Nov 2006
+2 more trials
GSK
GSKLONDON, United Kingdom
1 program
1
3APSPhase 31 trial
Active Trials
NCT00088673Unknown950
M&
1 program
1
Investigational drugPhase 31 trial
Active Trials
NCT00006187TerminatedEst. Jun 2005
AS
1 program
1
MasitinibPhase 3Small Molecule1 trial
Active Trials
NCT01872598CompletedEst. Dec 2020
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
6 programs
5
1
TalsaclidinePhase 2/31 trial
BI 409306Phase 21 trial
BI 425809 dose 1Phase 21 trial
NS 2330Phase 21 trial
TalsaclidinePhase 21 trial
+1 more programs
Active Trials
NCT02240693Completed128Est. Oct 2017
NCT02788513Completed611Est. Oct 2019
NCT00153010Completed430
+3 more trials
Pfizer
PfizerNEW YORK, NY
13 programs
9
3
DonepezilPhase 21 trial
bapineuzumabPhase 2Monoclonal Antibody
lecozotan SRPhase 21 trial
LecozotanPhase 11 trial
Lecozotan SRPhase 11 trial
+8 more programs
Active Trials
NCT00366288Completed56Est. Mar 2008
NCT00563732CompletedEst. Sep 2008
NCT00366483Completed40
+13 more trials
E
6 programs
1
5
DONEPEZIL HYDROCHLORIDEPhase 21 trial
DonepezilPhase 2
E2609Phase 21 trial
Lemborexant 10 mgPhase 21 trial
Lemborexant 25 mgPhase 21 trial
+1 more programs
Active Trials
NCT04971733Completed8Est. May 2024
NCT00165659Completed
NCT02322021Terminated70Est. Dec 2019
+2 more trials
Acumen Pharmaceuticals
3 programs
2
1
sabirnetugPhase 21 trial
ACU193Phase 11 trial
sabirnetugPhase 11 trial
Active Trials
NCT04931459CompletedEst. Jun 2023
NCT06511570CompletedEst. Sep 2024
NCT06335173Active Not RecruitingEst. Oct 2026
NKGEN Biotech
NKGEN BiotechCA - Santa Ana
2 programs
1
1
SNK01Phase 21 trial
SNK01Phase 11 trial
Active Trials
NCT04678453Terminated10Est. Jan 2024
NCT07228078Recruiting30Est. Apr 2028
Voyager Therapeutics
2 programs
2
Leuprolide acetatePhase 21 trial
Leuprolide acetatePhase 21 trial
Active Trials
NCT00063310CompletedEst. Feb 2006
NCT00076440CompletedEst. Mar 2007
Alector
1 program
1
AL002Phase 21 trial
Active Trials
NCT04592874CompletedEst. Sep 2024
Biogen
BiogenCAMBRIDGE, MA
1 program
1
E2609Phase 2
Ipsen
1 program
1
EGb 761®Phase 21 trial
Active Trials
NCT00500500Terminated40Est. Apr 2008
Formosa Pharmaceuticals
1 program
1
EX039Phase 21 trial
Active Trials
NCT05413655Recruiting120Est. Feb 2027
IGC Pharma
1 program
1
IGC-AD1-ActivePhase 21 trial
Active Trials
NCT05543681RecruitingEst. Mar 2026
UP
1 program
1
LevetiracetamPhase 21 trial
Active Trials
NCT03489044Completed8Est. Mar 2022
N
NeurocentriaCA - Walnut Creek
1 program
1
MMFS-205-SRPhase 21 trial
Active Trials
NCT03531684CompletedEst. Apr 2020
P
1 program
1
Normal Saline along with standard treatmentPhase 21 trial
Active Trials
NCT04052737Completed80Est. Jan 2023
Vivoryon Therapeutics
Vivoryon TherapeuticsGermany - Halle
1 program
1
PQ912Phase 21 trial
Active Trials
NCT03919162TerminatedEst. Aug 2024
Biohaven
1 program
1
troriluzolePhase 2Small Molecule1 trial
Active Trials
NCT03605667CompletedEst. Dec 2021
Lexeo Therapeutics
Lexeo TherapeuticsNY - New York
2 programs
1
1
LX1001Phase 1/21 trial
LX1001Phase 11 trial
Active Trials
NCT05400330Active Not Recruiting10Est. Nov 2028
NCT03634007Completed15Est. Nov 2024
Alzamend Neuro
1 program
1
ALZN002Phase 1/21 trial
Active Trials
NCT05834296Active Not RecruitingEst. Mar 2028
Arrowhead Pharmaceuticals
1 program
1
ARO-MAPT-SCPhase 1/21 trial
Active Trials
NCT07221344Recruiting112Est. Jun 2027
Vaccinex
VaccinexROCHESTER, NY
1 program
1
PepinemabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT04381468CompletedEst. Jun 2024
Bristol Myers Squibb
3 programs
3
BMS-708163Phase 14 trials
BMS-708163Phase 11 trial
galantaminePhase 11 trial
Active Trials
NCT01002079Completed20Est. Oct 2010
NCT01042314Completed18Est. Apr 2010
NCT00901498Completed36Est. Jul 2009
+3 more trials

+25 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.Investigational drug
Eli Lilly and CompanyP-tau217 Test
Life Molecular Imaging[18F]PI-2620
Eli Lilly and CompanyDonanemab
Life Molecular ImagingNilotinib BE 84mg
AB ScienceMasitinib
Life Molecular ImagingFlorbetaben
GSK3APS
Sanofixaliproden
Sanofixaliproden
Johnson & Johnsongalantamine hydrobromide
Johnson & Johnsongalantamine
Johnson & Johnsongalantamine hydrobromide
Johnson & Johnsongalantamine hydrobromide
Boehringer IngelheimTalsaclidine

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 14,865 patients across 50 trials

NCT00000174NovartisRivastigmine

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

Phase 3Completed
NCT00006187Merck & Co.Investigational drug

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Est. completion: Jun 2005
Phase 3Terminated
NCT07142954Eli Lilly and CompanyP-tau217 Test

Epidemiology and Biomarker Study in Alzheimer's Disease

Start: Aug 2025Est. completion: Jul 20333,400 patients
Phase 3Recruiting
NCT05641688Life Molecular Imaging[18F]PI-2620

[18F]PI-2620 Phase 3 Histopathological Study

Start: Dec 2022Est. completion: Jun 2027
Phase 3Recruiting
NCT05508789Eli Lilly and CompanyDonanemab

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Start: Oct 2022Est. completion: Jul 20281,500 patients
Phase 3Recruiting
NCT05143528Life Molecular ImagingNilotinib BE 84mg

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

Start: Feb 2022Est. completion: Jun 2026
Phase 3Not Yet Recruiting
NCT01872598AB ScienceMasitinib

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Start: Jan 2012Est. completion: Dec 2020
Phase 3Completed
NCT01020838Life Molecular ImagingFlorbetaben

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Start: Nov 2009Est. completion: Dec 2013
Phase 3Completed
NCT00088673GSK3APS

Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease

Start: Jun 2004950 patients
Phase 3Unknown
NCT00103649Sanofixaliproden

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Start: Nov 2003Est. completion: Oct 20071,306 patients
Phase 3Completed
NCT00104013Sanofixaliproden

Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Start: Nov 2003Est. completion: Nov 20071,455 patients
Phase 3Completed
NCT00253214Johnson & Johnsongalantamine hydrobromide

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Start: Mar 2001Est. completion: Jul 2002973 patients
Phase 3Completed
NCT00304629Johnson & Johnsongalantamine

Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease

Start: Mar 2000Est. completion: Mar 2002241 patients
Phase 3Completed
NCT00261573Johnson & Johnsongalantamine hydrobromide

A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Start: Dec 1998Est. completion: Dec 2000593 patients
Phase 3Completed
NCT00253188Johnson & Johnsongalantamine hydrobromide

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Start: Feb 1997Est. completion: Dec 1998653 patients
Phase 3Completed
NCT02248116Boehringer IngelheimTalsaclidine

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

Start: May 1999198 patients
Phase 2/3Terminated
NCT07228078NKGEN BiotechSNK01

Open-Label Extension Protocol to SNK01-AD01 Study

Start: Jun 2025Est. completion: Apr 202830 patients
Phase 2Recruiting
NCT06274528EisaiLemborexant 10 mg

DORA and LP in Alzheimer's Disease Biomarkers

Start: Mar 2024Est. completion: Mar 2029201 patients
Phase 2Recruiting
NCT06335173Acumen Pharmaceuticalssabirnetug

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

Start: Feb 2024Est. completion: Oct 2026
Phase 2Active Not Recruiting
NCT05728736EisaiLemborexant 25 mg

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Start: Mar 2023Est. completion: Oct 20230
Phase 2Withdrawn
NCT05543681IGC PharmaIGC-AD1-Active

Clinical Trial on Agitation in Alzheimer's Dementia

Start: Oct 2022Est. completion: Mar 2026
Phase 2Recruiting
NCT05413655Formosa PharmaceuticalsEX039

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

Start: Aug 2022Est. completion: Feb 2027120 patients
Phase 2Recruiting
NCT03919162Vivoryon TherapeuticsPQ912

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Start: Nov 2021Est. completion: Aug 2024
Phase 2Terminated
NCT04592874AlectorAL002

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Start: Jan 2021Est. completion: Sep 2024
Phase 2Completed
NCT03489044UCB PharmaLevetiracetam

An Investigation of Levetiracetam in Alzheimer's Disease

Start: Oct 2018Est. completion: Mar 20228 patients
Phase 2Completed
NCT03605667Biohaventroriluzole

Study of BHV-4157 in Alzheimer's Disease

Start: Jul 2018Est. completion: Dec 2021
Phase 2Completed
NCT04052737PharmazzNormal Saline along with standard treatment

PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

Start: Mar 2018Est. completion: Jan 202380 patients
Phase 2Completed
NCT03531684NeurocentriaMMFS-205-SR

Efficacy and Safety of MMFS in Early AD

Start: Mar 2018Est. completion: Apr 2020
Phase 2Completed
NCT02788513Boehringer IngelheimBI 425809 dose 1

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Start: Aug 2016Est. completion: Oct 2019611 patients
Phase 2Completed
NCT02240693Boehringer IngelheimBI 409306

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Start: Jan 2015Est. completion: Oct 2017128 patients
Phase 2Completed
NCT02322021EisaiE2609

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Start: Nov 2014Est. completion: Dec 201970 patients
Phase 2Terminated
NCT00750282Life Molecular ImagingFlorbetaben

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Start: Aug 2008Est. completion: Nov 2010
Phase 2Completed
NCT00151398Pfizerlecozotan SR

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

Start: Oct 2005Est. completion: Mar 2008229 patients
Phase 2Completed
NCT00500500IpsenEGb 761®

Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

Start: Jul 2005Est. completion: Apr 200840 patients
Phase 2Terminated
NCT00285025SanofiSR57667B

Study of the Effect of SR57667B in Patients With Alzheimer's Disease

Start: Mar 2005Est. completion: Sep 2005500 patients
Phase 2Completed
NCT00285077SanofiSR57667B

Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease

Start: Mar 2004Est. completion: Nov 2006390 patients
Phase 2Completed
NCT00076440Voyager TherapeuticsLeuprolide acetate

Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study

Start: Dec 2003Est. completion: Mar 2007
Phase 2Completed
NCT00063310Voyager TherapeuticsLeuprolide acetate

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

Start: Mar 2003Est. completion: Feb 2006
Phase 2Completed
NCT00153010Boehringer IngelheimNS 2330

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Start: Feb 2003430 patients
Phase 2Completed
NCT00165659EisaiDONEPEZIL HYDROCHLORIDE

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Start: Nov 2002
Phase 2Completed
NCT02249351Boehringer IngelheimTalsaclidine

Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type

Start: Dec 199954 patients
Phase 2Terminated
NCT00006399PfizerDonepezil

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Start: Sep 1999Est. completion: Mar 200445 patients
Phase 2Completed
NCT02249403Boehringer IngelheimTalsaclidine 6 mg

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Start: Jan 1999362 patients
Phase 2Completed
NCT07221344Arrowhead PharmaceuticalsARO-MAPT-SC

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Start: Nov 2025Est. completion: Jun 2027112 patients
Phase 1/2Recruiting
NCT05834296Alzamend NeuroALZN002

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Start: Jul 2023Est. completion: Mar 2028
Phase 1/2Active Not Recruiting
NCT04381468VaccinexPepinemab

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Start: Jul 2021Est. completion: Jun 2024
Phase 1/2Completed
NCT04971733EisaiE2814

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Start: Jun 2021Est. completion: May 20248 patients
Phase 1/2Completed
NCT03634007Lexeo TherapeuticsLX1001

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

Start: Nov 2019Est. completion: Nov 202415 patients
Phase 1/2Completed
NCT00380302SanofiAVE1625

Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

Start: Sep 2006Est. completion: Jul 2007162 patients
Phase 1/2Completed
NCT06673069Ionis PharmaceuticalsION269

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

Start: Dec 2024Est. completion: Dec 20251 patients
Phase 1Terminated

Related Jobs in Neurology

Associate Director, HCP Marketing - Parkinson's Disease

AbbVie
Mettawa, IL
2h ago

Clinical Trial Manager/Senior Clinical Trial Manager

Axsome Therapeutics
New York, NY
3h ago
$130K - $150K/yr

Specialty Account Manager, Auvelity (Hammond, IN)

Axsome Therapeutics
Hammond, IN
15h ago
$100K - $150K/yr

Specialty Account Manager, Symbravo (Indianapolis N, IN)

Axsome Therapeutics
Indianapolis, IN
22h ago
$100K - $150K/yr

Specialty Account Manager, Sunosi (Indianapolis N, IN)

Axsome Therapeutics
Indianapolis, IN
22h ago
$110K - $150K/yr

Medical Science Liaison/Senior Medical Science Liaison, Migraine (Southeast)

Axsome Therapeutics
Miami, FL
Yesterday
$150K - $200K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

14 late-stage (Phase 3) programs — potential near-term approvals
8 actively recruiting trials targeting 14,865 patients
30 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)Amyotrophic Lateral Sclerosis(77)